RBQM Podcast Series | Episode 3: Staying within the Guardrails: How to Push the Boundaries in a Highly Regulated Industry

By designing quality into trials, we focus on the most critical data and create a framework for efficiently identifying and addressing any risks to patients, the integrity of data, or regulatory compliance. While part of regulatory guidance, consistent interpretation of RBQM approaches by regulatory inspectors is an area of concern. In such a highly regulated industry that is notably slow to adopt change, biopharmaceutical companies and CROs are still debating how to go with evidence-backed documentation to satisfy regulatory requirements when using risk-based approaches.

In the third episode of our RBQM podcast series, Amy Kissam-Sands, Senior Vice President of Clinical Operations, John Bell, Chief Quality Officer, and Dr. Kristin Murphy, Senior Director and Global Head of the Change and Adoption Center of Excellence, discuss how to work within the regulatory guardrails when establishing a risk assessment framework.

 

Return to Insights Center

Related Insights

Blog

Leveraging the draft FDA Guidance on PBPK for your drug development program

Feb 24, 2021

Playbook

Are you using real-world evidence?

Feb 1, 2023

Blog

AI Milestones: FDA’s ISTAND program accepts AI-based assessment tool for depression

Mar 19, 2024

Blog

Summary and assessment: Using Artificial Intelligence & Machine Learning in the Development of Drug & Biological Products: Discussion Paper and Request for Feedback (FDA)

Mar 7, 2024

Blog

Summary and assessment of EMA’s reflection paper on the use of artificial intelligence (AI) in the medicinal product lifecycle

Mar 7, 2024

Blog

Regulatory acceptability of AI: Current perspectives

Mar 7, 2024

Blog

BIOSECURE Act: Implications for US-based drug developers

Apr 10, 2024

Article

8 things you need to know about eCTDs in China

Jul 1, 2022

Blog

CNS Summit Recap: The Future is Collaborative

Nov 22, 2021

Video

Creating EU-CTR compliant and patient-friendly lay language summaries (LLS)

Jan 26, 2022

Article

New endpoints for early-stage cancer are gaining regulatory traction

Jan 28, 2022

Article

How biotechs can strengthen their value story with advanced analytics

Feb 15, 2022